Biologic therapies for moderate to severe psoriasis are not interchangeable;Los tratamientos biológicos de la psoriasis moderada a grave no son alternativas terapéuticas equivalentes

Actas Dermo-Sifiliograficas

Volumn 105, Issue 5, 2014, Pages 483-486

  Puig, L ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Adalimumab; Biologic agents; Clinical equivalence; Etanercept; Infliximab; Meta analysis; Psoriasis; Ustekinumab

Indexed keywords

ETANERCEPT; INFLIXIMAB; BIOLOGICAL PRODUCT;

ARTICLE; BIOLOGICAL THERAPY; CLINICAL DECISION MAKING; DISEASE SEVERITY; DRUG EFFICACY; HUMAN; META ANALYSIS (TOPIC); PSORIASIS; SEVERITY OF ILLNESS INDEX; THERAPEUTIC EQUIVALENCE;

BIOLOGICAL PRODUCTS; HUMANS; PSORIASIS; SEVERITY OF ILLNESS INDEX; THERAPEUTIC EQUIVALENCY;

EID: 84901619113     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.adengl.2014.04.019     Document Type: Short Survey

References (10)

1. M. Galván-Banqueri, R. Marín Gil, B. Santos Ramos, and F.J. Bautista Paloma Biological treatments for moderate-to-severe psoriasis: Indirect comparison J Clin Pharm Ther 38 2013 121 130
2. R. Jaeschke, J. Singer, and G.H. Guyatt Ascertaining the minimal clinically important difference Cont Clin Trials 10 1989 407 415
3. K. Reich, A.D. Burden, J.N. Eaton, and N.S. Hawkins Efficacy of biologics in the treatment of moderate to severe psoriasis: A network meta-analysis of randomized controlled trials Br J Dermatol 166 2012 179 188
4. T.C. Lucka, D. Pathirana, A. Sammain, F. Bachmann, S. Rosumeck, and R. Erdmann et al. Efficacy of systemic therapies for moderate-to-severe psoriasis: A systematic review and meta-analysis of long-term treatment J Eur Acad Dermatol Venereol 26 2012 1331 1344
5. V.W. Lin, S. Ringold, and E.B. Devine Comparison of ustekinumab with other biological agents for the treatment of moderate to severe plaque psoriasis: A bayesian network meta-analysis Arch Dermatol 148 2012 1403 1410
6. H.C. Bucher, G.H. Guyatt, L.E. Griffith, and S.D. Walter The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials J Clin Epidemiol 50 1997 683 691
7. Indirect Evidence: Indirect Treatment Comparisons in Meta-Analysis. © 2013 Canadian Agency for Drugs and Technologies in Health. [acceso 12 Jul 2013]. Disponible en: http://www.cadth.ca/en/products/methods-and-guidelines/ publication/884
8. Critical Appraisal Skills Programme (CASP) España. Herramientas de actuación. [acceso 12 Jul 2013]. Disponible en: http://redcaspe.org/ drupal/?q=node/30
9. S. Fénix-Caballero, E.J. Alegre-del Rey, R. Castaño-Lara, F. Puigventós-Latorre, J.M. Borrero-Rubio, and J.F. López-Vallejo Direct and indirect comparison of the efficacy and safety of adalimumab, etanercept, infliximab and golimumab in psoriatic arthritis J Clin Pharm Ther 38 2013 286 293
10. A. Nast, B. Sporbeck, S. Rosumeck, D. Pathirana, A. Jacobs, and R.N. Werner et al. Which antipsoriatic drug has the fastest onset of action?-Systematic review on the rapidity of the onset of action J Invest Dermatol 133 2013 1963 1970